1
|
Pagel J, Reddy N, Jagadeesh D, Stathis A, Asch AS, Salman H, Kenkre VP, Soumerai JD, Llorin‐Sangalang J, Gorbatchevsky I, Li J, Zelenetz AD. ZANDELISIB, A PI3Kδ INHIBITOR ON INTERMITTENT SCHEDULE (IS) IN FOLLICULAR LYMPHOMA PATIENTS WHO PROGRESSED WITHIN 24 MONTHS OF FIRST‐LINE CHEMOIMUNOTHERAPY (POD24). Hematol Oncol 2021. [DOI: 10.1002/hon.25_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- J. Pagel
- Swedish Cancer Institute Hematology and Oncology Seattle Washington USA
| | - N. Reddy
- Vanderbilt University Medical Center Hematology and Oncology Nashville USA
| | - D. Jagadeesh
- Cleveland Clinic, Hematology and Medical Oncology Cleveland USA
| | - A. Stathis
- IOSI‐Oncology Institute of Southern Switzerland Ospedale Regionale Di Bellinzona E Valli, Oncology Bellinzona Switzerland
| | - A. S. Asch
- University of Oklahoma Health Sciences Center‐ Stephenson Cancer Center Hematology and Oncology Oklahoma City USA
| | - H. Salman
- Stony Brook Medical Center Hematology and Oncology Stony Brook USA
| | - V. P. Kenkre
- Carbone Cancer Center Hematology and Oncology Madison USA
| | - J. D. Soumerai
- Massachusetts General Hospital Hematology and Oncology Boston USA
| | | | | | - J. Li
- MEI Pharma, Inc Biometrics San Diego USA
| | - A. D. Zelenetz
- Memorial Sloan Kettering Cancer Center Hematology and Oncology New York City USA
| |
Collapse
|
2
|
Graspeuntner S, Waschina S, Künzel S, Twisselmann N, Rausch TK, Cloppenborg-Schmidt K, Zimmermann J, Viemann D, Herting E, Göpel W, Baines JF, Kaleta C, Rupp J, Härtel C, Pagel J. Gut Dysbiosis With Bacilli Dominance and Accumulation of Fermentation Products Precedes Late-onset Sepsis in Preterm Infants. Clin Infect Dis 2020; 69:268-277. [PMID: 30329017 DOI: 10.1093/cid/ciy882] [Citation(s) in RCA: 48] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2018] [Accepted: 10/12/2018] [Indexed: 12/30/2022] Open
Abstract
BACKGROUND Gut dysbiosis has been suggested as a major risk factor for the development of late-onset sepsis (LOS), a main cause of mortality and morbidity in preterm infants. We aimed to assess specific signatures of the gut microbiome, including metabolic profiles, in preterm infants <34 weeks of gestation preceding LOS. METHODS In a single-center cohort, fecal samples from preterm infants were prospectively collected during the period of highest vulnerability for LOS (days 7, 14, and 21 of life). Following 16S rRNA gene profiling, we assessed microbial community function using microbial metabolic network modeling. Data were adjusted for gestational age and use of probiotics. RESULTS We studied stool samples from 71 preterm infants with LOS and 164 unaffected controls (no LOS/necrotizing enterocolitis). In most cases, the bacteria isolated in diagnostic blood culture corresponded to the genera in the gut microbiome. LOS cases had a decelerated development of microbial diversity. Before onset of disease, LOS cases had specific gut microbiome signatures with higher abundance of Bacilli (specifically coagulase-negative Staphylococci) and a lack of anaerobic bacteria. In silico modeling of bacterial community metabolism suggested accumulation of the fermentation products ethanol and formic acid in LOS cases before the onset of disease. CONCLUSIONS Intestinal dysbiosis preceding LOS is characterized by an accumulation of Bacilli and their fermentation products and a paucity of anaerobic bacteria. Early microbiome and metabolic patterns may become a valuable biomarker to guide individualized prevention strategies of LOS in highly vulnerable populations.
Collapse
Affiliation(s)
- S Graspeuntner
- Department of Infectious Diseases and Microbiology, University of Lübeck, Plön
| | - S Waschina
- Research Group Medical Systems Biology, Christian Albrechts University of Kiel, Plön
| | - S Künzel
- Max Planck Institute for Evolutionary Biology, Evolutionary Genomics, Plön
| | - N Twisselmann
- Department of Pediatrics, University of Lübeck, Lübeck, Germany
| | - T K Rausch
- Department of Pediatrics, University of Lübeck, Lübeck, Germany.,Institute for Medical Biometry and Statistics, University of Lübeck, Lübeck, Germany
| | - K Cloppenborg-Schmidt
- Institute for Experimental Medicine, Christian Albrechts University of Kiel, Lübeck, Germany
| | - J Zimmermann
- Research Group Medical Systems Biology, Christian Albrechts University of Kiel, Plön
| | - D Viemann
- Department of Pediatric Pneumology, Allergy and Neonatology, Hannover Medical School, Lübeck, Germany
| | - E Herting
- Department of Pediatrics, University of Lübeck, Lübeck, Germany
| | - W Göpel
- Department of Pediatrics, University of Lübeck, Lübeck, Germany
| | - J F Baines
- Max Planck Institute for Evolutionary Biology, Evolutionary Genomics, Plön.,Institute for Medical Biometry and Statistics, University of Lübeck, Lübeck, Germany
| | - C Kaleta
- Research Group Medical Systems Biology, Christian Albrechts University of Kiel, Plön
| | - J Rupp
- Department of Infectious Diseases and Microbiology, University of Lübeck, Plön.,German Center for Infection Research, partner site Hamburg-Lübeck-Borstel-Riems, Lübeck, Germany
| | - C Härtel
- Department of Pediatrics, University of Lübeck, Lübeck, Germany
| | - J Pagel
- Department of Infectious Diseases and Microbiology, University of Lübeck, Plön.,Department of Pediatrics, University of Lübeck, Lübeck, Germany.,German Center for Infection Research, partner site Hamburg-Lübeck-Borstel-Riems, Lübeck, Germany
| |
Collapse
|
3
|
Zelenetz A, Jagadeesh D, Kenkre V, Reddy N, Stathis A, Salman H, Asch A, Soumerai J, Jhangiani H, Iasonos A, Patel K, Carter J, LLorin-Sangalang J, Pagel J. THE PI3Kδ INHIBITOR ME-401 ± RITUXIMAB IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND SMALL LYMPHOCYTIC LYMPHOMA (SLL). Hematol Oncol 2019. [DOI: 10.1002/hon.133_2629] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- A.D. Zelenetz
- Lymphoma; Memorial Sloane Kettering Cancer Center; New York City United States
| | - D. Jagadeesh
- Hematology; Cleveland Clinic Taussig Cancer Institute; Cleveland United States
| | - V.P. Kenkre
- Hematology; University of Wisconsin Medical Center; Madison United States
| | - N.M. Reddy
- Hematology; Vanderbilt University Ingram Cancer Center; Nashville United States
| | - A. Stathis
- Hematology; IOSI - Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - H.S. Salman
- Hematology; Stony Brook Medical Center; Stony Brook United States
| | - A.S. Asch
- Hematology; University of Oklahoma Stephenson Cancer Center; Oklahoma United States
| | - J. Soumerai
- Hematology; Massachussets General Hospital; Boston United States
| | - H.S. Jhangiani
- Hematology/Oncology; Compassionate Care Cancer Center; Fountain Valley United States
| | - A. Iasonos
- Lymphoma; Memorial Sloane Kettering Cancer Center; New York City United States
| | - K. Patel
- Hematology; Swedish Cancer Institute; Seattle United States
| | - J. Carter
- Lymphoma; Memorial Sloane Kettering Cancer Center; New York City United States
| | | | - J.M. Pagel
- Hematology; Swedish Cancer Institute; Seattle United States
| |
Collapse
|
4
|
Gregory G, Walker P, Mahadevan D, Wang D, Chang J, Hernandez-Ilizaliturri F, Klein A, Rybka W, Wagner-Johnston N, Escobar C, Pagel J, Mohrbacher A, Opat S, Shortt J, Ma H, Gwo J, Farooqui M, Quach H. ANTITUMOR ACTIVITY OF PEMBROLIZUMAB PLUS DINACICLIB IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA: THE PHASE 1B KEYNOTE-155 STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.140_2630] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- G. Gregory
- Hematology; School of Clinical Sciences at Monash Health, Monash University; Clayton Australia
| | - P. Walker
- Clinical; Peninsula Health; Frankston Australia
| | - D. Mahadevan
- Medicine; The University of Arizona Cancer Center; Tucson United States
| | - D. Wang
- Hematology/Oncology; Henry Ford Hospital; Detroit United States
| | - J. Chang
- Oncology; Wisconsin Institute of Medical Research; Madison United States
| | | | - A. Klein
- Hematology/Oncology; Tufts Medical Center; Boston United States
| | - W. Rybka
- Oncology; Penn State Hershey Cancer Institute; Hershey United States
| | - N. Wagner-Johnston
- Oncology; Johns Hopkins Sidney Kimmel Cancer Center; Baltimore United States
| | - C. Escobar
- Oncology; Baylor University Medical Center; Dallas United States
| | - J.M. Pagel
- Hematology; Swedish Cancer Institute; Seattle United States
| | - A. Mohrbacher
- Hematology; Keck School of Medicine of USC; Los Angeles United States
| | - S. Opat
- Hematology; School of Clinical Sciences at Monash Health, Monash University; Clayton Australia
| | - J. Shortt
- Hematology; School of Clinical Sciences at Monash Health, Monash University; Clayton Australia
| | - H. Ma
- Biostatistics; Merck & Co., Inc.; Kenilworth NJ United States
| | - J. Gwo
- Biostatistics; Merck & Co., Inc.; Kenilworth NJ United States
| | - M. Farooqui
- Clinical Research; Merck & Co., Inc.; Kenilworth United States
| | - H. Quach
- Hematology; University of Melbourne, St. Vincent's Hospital; Fitzroy Australia
| |
Collapse
|
5
|
Mato A, Barrientos J, Brander D, Pagel J, Gutierrez M, Kadish K, Tomlinson B, Ghosh N, Giafis N, Ipe D, Upasani S, Sundaram M, Ferrante L, Amaya-Chanaga C, Iyengar R, Sharman J. PF383 PROGNOSTIC TESTING AND TREATMENT APPROACHES BASED ON REAL-WORLD CLINICAL EXPERIENCE FROM AN INTERIM ANALYSIS OF THE INFORMCLL REGISTRY OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA. Hemasphere 2019. [DOI: 10.1097/01.hs9.0000559744.42031.cf] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
6
|
Mato A, Schuster S, Lamanna N, Pagel J, Flinn I, Barrientos J, Reeves J, Cheson B, Barr P, Kambhampati S, Lansigan F, Pu J, Skarbnik A, Fonseca G, Dorsey C, LaRatta N, Weissbrot H, Svoboda J, Luning Prak E, Tsao P, Sitlinger A, Paskalis D, Sportelli P, Miskin H, Weiss M, Brander D. A PHASE 2 STUDY TO ASSESS THE SAFETY AND EFFICACY OF UMBRALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO ARE INTOLERANT TO PRIOR BTK OR PI3K DELTA INHIBITOR THERAPY. Hematol Oncol 2019. [DOI: 10.1002/hon.56_2629] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- A.R. Mato
- CLL Program; Leukemia Service, Memorial Sloan-Kettering Cancer Center; New York NY United States
| | - S.J. Schuster
- Lymphoma Department; University of Pennsylvania, Abramson Cancer Center; Philadelphia PA United States
| | - N. Lamanna
- Columbia University Medical Center; New York-Presbyterian; New York United States
| | - J.M. Pagel
- Department of Hematology; Swedish Cancer Institute; Seattle WA United States
| | - I.W. Flinn
- TN Oncology; Sarah Cannon Research Institute; Nashville TN United States
| | - J. Barrientos
- CLL Research and Treatment Program; Northwell Health; New Hyde Park NY United States
| | - J.A. Reeves
- Florida Cancer Specialists; Sarah Cannon Research Institute; Fort Myers FL United States
| | - B.D. Cheson
- Lombardi Comprehensive Cancer Center; Georgetown University Hospital; Washington DC United States
| | - P.M. Barr
- Wilmot Cancer Institute; University of Rochester; Rochester NY United States
| | - S. Kambhampati
- Research Medical Center; Sarah Cannon Research Institute; Kansas City MO United States
| | - F. Lansigan
- Department of Hematology; Dartmouth-Hitchcock Medical Center; Lebanon NH United States
| | - J.J. Pu
- Department of Hematology; Penn State Health; Hershey PA United States
| | - A. Skarbnik
- Department of Hematology; John Theurer Cancer Center; Hackensack NJ United States
| | - G. Fonseca
- Florida Cancer Specialists North; Sarah Cannon Research Institute; St. Petersburg FL United States
| | - C. Dorsey
- CLL Program; Leukemia Service, Memorial Sloan-Kettering Cancer Center; New York NY United States
| | - N.M. LaRatta
- Lymphoma Department; University of Pennsylvania, Abramson Cancer Center; Philadelphia PA United States
| | - H. Weissbrot
- Columbia University Medical Center; New York-Presbyterian; New York United States
| | - J. Svoboda
- Lymphoma Department; University of Pennsylvania, Abramson Cancer Center; Philadelphia PA United States
| | - E.T. Luning Prak
- Clinical Immunology Laboratory; University of Pennsylvania; Philadelphia PA United States
| | - P. Tsao
- Clinical Immunology Laboratory; University of Pennsylvania; Philadelphia PA United States
| | - A. Sitlinger
- Department of Hematology; Duke University Medical Center; Durham NC United States
| | - D. Paskalis
- Clinical Development; TG Therapeutics, Inc.; New York NY United States
| | - P. Sportelli
- Clinical Development; TG Therapeutics, Inc.; New York NY United States
| | - H.P. Miskin
- Clinical Development; TG Therapeutics, Inc.; New York NY United States
| | - M.S. Weiss
- Clinical Development; TG Therapeutics, Inc.; New York NY United States
| | - D.M. Brander
- Department of Hematology; Duke University Medical Center; Durham NC United States
| |
Collapse
|
7
|
Schwarz J, Scheckenbach V, Kugel H, Spring B, Pagel J, Härtel C, Pauluschke-Fröhlich J, Peter A, Poets CF, Gille C, Köstlin N. Granulocytic myeloid-derived suppressor cells (GR-MDSC) accumulate in cord blood of preterm infants and remain elevated during the neonatal period. Clin Exp Immunol 2017; 191:328-337. [PMID: 28963753 DOI: 10.1111/cei.13059] [Citation(s) in RCA: 44] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/22/2017] [Indexed: 12/17/2022] Open
Abstract
Preterm delivery is the leading cause of perinatal morbidity and mortality. Among the most important complications in preterm infants are peri- or postnatal infections. Myeloid-derived suppressor cells (MDSC) are myeloid cells with suppressive activity on other immune cells. Emerging evidence suggests that granulocytic MDSC (GR-MDSC) play a pivotal role in mediating maternal-fetal tolerance. The role of MDSC for postnatal immune-regulation in neonates is incompletely understood. Until the present time, nothing was known about expression of MDSC in preterm infants. In the present pilot study, we quantified GR-MDSC counts in cord blood and peripheral blood of preterm infants born between 23 + 0 and 36 + 6 weeks of gestation (WOG) during the first 3 months of life and analysed the effect of perinatal infections. We show that GR-MDSC are increased in cord blood independent of gestational age and remain elevated in peripheral blood of preterm infants during the neonatal period. After day 28 they drop to nearly adult levels. In case of perinatal or postnatal infection, GR-MDSC accumulate further and correlate with inflammatory markers C-reactive protein (CRP) and white blood cell counts (WBC). Our results point towards a role of GR-MDSC for immune-regulation in preterm infants and render them as a potential target for cell-based therapy of infections in these patients.
Collapse
Affiliation(s)
- J Schwarz
- Department of Neonatology, Tuebingen University Children's Hospital, Tuebingen, Germany
| | - V Scheckenbach
- Department of Neonatology, Tuebingen University Children's Hospital, Tuebingen, Germany
| | - H Kugel
- Department of Neonatology, Tuebingen University Children's Hospital, Tuebingen, Germany
| | - B Spring
- Department of Neonatology, Tuebingen University Children's Hospital, Tuebingen, Germany
| | - J Pagel
- Department of Pediatrics, University Clinic Schleswig Holstein, Campus Lübeck, Lübeck, Germany
| | - C Härtel
- Department of Obstetrics and Gynecology, University Hospital Tuebingen, Germany
| | | | - A Peter
- German Centre for Diabetes Research (DZD), Tuebingen, Germany.,Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Centre Munich at the University of Tuebingen, Tuebingen, Germany.,Division of Endocrinology, Diabetology, Angiology, Nephrology and Clinical Chemistry, Department of Internal Medicine, Tuebingen University Hospital, Tuebingen, Germany
| | - C F Poets
- Department of Neonatology, Tuebingen University Children's Hospital, Tuebingen, Germany
| | - C Gille
- Department of Neonatology, Tuebingen University Children's Hospital, Tuebingen, Germany
| | - N Köstlin
- Department of Neonatology, Tuebingen University Children's Hospital, Tuebingen, Germany
| |
Collapse
|
8
|
Montillo M, Byrd J, Hillmen P, O'Brien S, Barrientos J, Reddy N, Coutre S, Tam C, Mulligan S, Jaeger U, Barr P, Furman R, Kipps T, Thornton P, Moreno C, Pagel J, Burger J, Jones J, Dai S, Vezan R, James D, Brown J. LONG-TERM EFFICACY AND SAFETY IN THE RESONATE STUDY: IBRUTINIB IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH UP TO FOUR YEARS FOLLOW-UP. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_98] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- M. Montillo
- Department of Haematology & Oncology; Niguarda Cancer Center, Niguarda Hospital; Milan Italy
| | - J.C. Byrd
- Division of Hematology, Department of Internal Medicine; The Ohio State University Comprehensive Cancer Center; Columbus USA
| | - P. Hillmen
- Department of Haematology; The Leeds Teaching Hospitals, St. James Institute of Oncology; Leeds UK
| | - S. O'Brien
- Chao Family Comprehensive Cancer Center; University of California Irvine; Orange USA
| | - J.C. Barrientos
- Division of Hematology and Medical Oncology; Department of Medicine, Hofstra Northwell School of Medicine; Hempstead USA
| | - N.M. Reddy
- Hematology/Oncology; Vanderbilt-Ingram Cancer Center; Nashville USA
| | - S. Coutre
- Division of Hematology, Stanford Cancer Center; Stanford University School of Medicine; Stanford USA
| | - C.S. Tam
- Department of Haematology, Peter MacCallum Cancer Centre and St. Vincent's Hospital; Melbourne Australia
| | - S.P. Mulligan
- Hematology; Royal North Shore Hospital, St. Leonards; Australia
| | - U. Jaeger
- Division of Hematology and Hemostaseology; Medical University of Vienna; Wien Austria
| | - P.M. Barr
- James P. Wilmot Cancer Center
- Department of Medicine, Hematology/Oncology; University of Rochester Medical Center; Rochester USA
| | - R.R. Furman
- Division of Hematology and Medical Oncology, Weill Cornell Medical College; New York USA
| | - T.J. Kipps
- Moores Cancer Center; University of California San Diego; La Jolla USA
| | - P. Thornton
- Department of Haematology; Beaumont Hospital; Dublin Republic of Ireland
| | - C. Moreno
- Hematology Department; Hospital de la Santa Creu Sant Pau; Barcelona Spain
| | - J.M. Pagel
- Hematologic Malignancies Program; Swedish Cancer Institute; Seattle USA
| | - J.A. Burger
- Department of Leukemia; University of Texas MD Anderson Cancer Center; Houston USA
| | - J. Jones
- Division of Hematology, Department of Internal Medicine; The Ohio State University Comprehensive Cancer Center; Columbus USA
| | - S. Dai
- Biostatistics; Pharmacyclics LLC, an AbbVie Company; Sunnyvale USA
| | - R. Vezan
- Clinical Research; Pharmacyclics LLC, an Abbvie Company; Sunnyvale USA
| | - D.F. James
- Clinical Research; Pharmacyclics LLC, an Abbvie Company; Sunnyvale USA
| | - J.R. Brown
- Division of Hematologic Malignancies; CLL Center, Dana-Farber Cancer Institute; Boston USA
| |
Collapse
|
9
|
Ghalie R, Pagel J, Soumerai J, Iasonos A, Patel K, Moreno O, Butler T, Zelenetz A. ME-401, A NOVEL, ORAL, POTENT AND SELECTIVE INHIBITOR OF PHOSPHATIDYLINOSITOL 3-KINASE P110δ (PI3Kδ) IN EARLY CLINICAL DEVELOPMENT FOR B-CELL LYMPHOID MALIGNANCIES. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_184] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- R.G. Ghalie
- Clinical Development, MEI Pharma; San Diego USA
| | - J.M. Pagel
- Center for Blood Disorders and Stem Cell Transplantation, Swedish Medical Center; Seattle USA
| | - J. Soumerai
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York City USA
| | - A. Iasonos
- Epidemiology and Statistics; Memorial Sloan Kettering Cancer Center; New York City USA
| | - K. Patel
- Center for Blood Disorders and Stem Cell Transplantation, Swedish Medical Center; Seattle USA
| | - O. Moreno
- Research & Development, MEI Pharma; San Diego USA
| | - T. Butler
- Clinical Development, MEI Pharma; San Diego USA
| | - A.D. Zelenetz
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York City USA
| |
Collapse
|
10
|
Schmid B, Nottebrock H, Esler KJ, Pagel J, Böhning-Gaese K, Schurr FM, Mueller T, Schleuning M. A bird pollinator shows positive frequency dependence and constancy of species choice in natural plant communities. Ecology 2016; 97:3110-3118. [PMID: 27870050 DOI: 10.1002/ecy.1565] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/01/2016] [Revised: 06/04/2016] [Accepted: 07/21/2016] [Indexed: 11/06/2022]
Abstract
Animal pollinators mediate reproduction of many plant species. Foraging theory suggests that animal pollinators exhibit preferences for common plant species in natural communities (positive frequency-dependent foraging) and temporary single-species specialization (flower constancy) during foraging bouts. Positive frequency dependence may favor common plant species; flower constancy may enhance conspecific pollen transfer particularly in rare plant species. Previous experimental studies suggest that avian pollinators are unlikely to exhibit these behaviors. We studied foraging behavior of Cape Sugarbirds (Promerops cafer), the main avian pollinator of many Protea species, using focal-plant and focal-bird sampling, assisted by high-resolution maps of the spatiotemporal distribution of Protea individuals and their flowering status. We found that Sugarbird's visitation preference increased with species' relative floral abundance, and that individual Sugarbirds tended to visit single species in sequence. Flower constancy during foraging bouts was significantly higher than expected from random plant-animal encounters at the scale of pollinator movements. Positive frequency dependence may favor the reproduction of abundant plant species while flower constancy may be particularly important for rare plant species. This first simultaneous study of both behaviors in a natural plant-pollinator system shows that bird pollinators exhibit both types of behavior and, in this way, possibly influence plant community structure.
Collapse
Affiliation(s)
- B Schmid
- Senckenberg Biodiversity and Climate Research Centre (BiK-F), Senckenberganlage 25, Frankfurt am Main, 60325, Germany.,Department of Conservation Biology and Entomology and Centre for Invasion Biology, Stellenbosch University, Private Bag X1, Matieland, 7602, South Africa.,Swiss Ornithological Institute, 6204, Sempach, Switzerland
| | - H Nottebrock
- Department of Conservation Biology and Entomology and Centre for Invasion Biology, Stellenbosch University, Private Bag X1, Matieland, 7602, South Africa.,Institute of Landscape and Plant Ecology, University of Hohenheim, August-von-Hartmann-Street 3, Stuttgart, 70599, Germany.,Institut des Sciences de l'Evolution, UMR 5554, Université Montpellier 2, Place Eugène Bataillon, Montpellier Cedex 05, F-34095, France
| | - K J Esler
- Department of Conservation Biology and Entomology and Centre for Invasion Biology, Stellenbosch University, Private Bag X1, Matieland, 7602, South Africa
| | - J Pagel
- Institute of Landscape and Plant Ecology, University of Hohenheim, August-von-Hartmann-Street 3, Stuttgart, 70599, Germany.,Institut des Sciences de l'Evolution, UMR 5554, Université Montpellier 2, Place Eugène Bataillon, Montpellier Cedex 05, F-34095, France
| | - K Böhning-Gaese
- Senckenberg Biodiversity and Climate Research Centre (BiK-F), Senckenberganlage 25, Frankfurt am Main, 60325, Germany.,Department of Biological Sciences, Johann Wolfgang Goethe-University, Max-von-Laue-Straße 9, Frankfurt am Main, 60438, Germany
| | - F M Schurr
- Institute of Landscape and Plant Ecology, University of Hohenheim, August-von-Hartmann-Street 3, Stuttgart, 70599, Germany.,Institut des Sciences de l'Evolution, UMR 5554, Université Montpellier 2, Place Eugène Bataillon, Montpellier Cedex 05, F-34095, France
| | - T Mueller
- Senckenberg Biodiversity and Climate Research Centre (BiK-F), Senckenberganlage 25, Frankfurt am Main, 60325, Germany.,Department of Biological Sciences, Johann Wolfgang Goethe-University, Max-von-Laue-Straße 9, Frankfurt am Main, 60438, Germany
| | - M Schleuning
- Senckenberg Biodiversity and Climate Research Centre (BiK-F), Senckenberganlage 25, Frankfurt am Main, 60325, Germany
| |
Collapse
|
11
|
Pagel J, Hartz A, Figge J, Gille C, Eschweiler S, Petersen K, Schreiter L, Hammer J, Karsten CM, Friedrich D, Herting E, Göpel W, Rupp J, Härtel C. Regulatory T cell frequencies are increased in preterm infants with clinical early-onset sepsis. Clin Exp Immunol 2016; 185:219-27. [PMID: 27163159 DOI: 10.1111/cei.12810] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2016] [Revised: 04/14/2016] [Accepted: 05/01/2016] [Indexed: 12/16/2022] Open
Abstract
The predisposition of preterm neonates to invasive infection is, as yet, incompletely understood. Regulatory T cells (Tregs ) are potential candidates for the ontogenetic control of immune activation and tissue damage in preterm infants. It was the aim of our study to characterize lymphocyte subsets and in particular CD4(+) CD25(+) forkhead box protein 3 (FoxP3)(+) Tregs in peripheral blood of well-phenotyped preterm infants (n = 117; 23 + 0 - 36 + 6 weeks of gestational age) in the first 3 days of life in comparison to term infants and adults. We demonstrated a negative correlation of Treg frequencies and gestational age. Tregs were increased in blood samples of preterm infants compared to term infants and adults. Notably, we found an increased Treg frequency in preterm infants with clinical early-onset sepsis while cause of preterm delivery, e.g. chorioamnionitis, did not affect Treg frequencies. Our data suggest that Tregs apparently play an important role in maintaining maternal-fetal tolerance, which turns into an increased sepsis risk after preterm delivery. Functional analyses are needed in order to elucidate whether Tregs have potential as future target for diagnostics and therapeutics.
Collapse
Affiliation(s)
- J Pagel
- Department of Pediatrics, University Clinic Schleswig Holstein, Campus Lübeck.,Department of Infectious Diseases and Microbiology, University of Lübeck
| | - A Hartz
- Department of Pediatrics, University Clinic Schleswig Holstein, Campus Lübeck.,Institute for Systemic Inflammation Research, University of Lübeck, Lübeck
| | - J Figge
- Institute for Systemic Inflammation Research, University of Lübeck, Lübeck
| | - C Gille
- Department of Neonatology, University of Tübingen, Tübingen, Germany
| | - S Eschweiler
- Institute for Systemic Inflammation Research, University of Lübeck, Lübeck
| | - K Petersen
- Department of Pediatrics, University Clinic Schleswig Holstein, Campus Lübeck
| | - L Schreiter
- Department of Pediatrics, University Clinic Schleswig Holstein, Campus Lübeck.,Institute for Systemic Inflammation Research, University of Lübeck, Lübeck
| | - J Hammer
- Department of Pediatrics, University Clinic Schleswig Holstein, Campus Lübeck
| | - C M Karsten
- Institute for Systemic Inflammation Research, University of Lübeck, Lübeck
| | - D Friedrich
- Department of Infectious Diseases and Microbiology, University of Lübeck
| | - E Herting
- Department of Pediatrics, University Clinic Schleswig Holstein, Campus Lübeck
| | - W Göpel
- Department of Pediatrics, University Clinic Schleswig Holstein, Campus Lübeck
| | - J Rupp
- Department of Infectious Diseases and Microbiology, University of Lübeck
| | - C Härtel
- Department of Pediatrics, University Clinic Schleswig Holstein, Campus Lübeck
| |
Collapse
|
12
|
Ghia P, Coutre S, Furman R, Sharman J, Cheson B, Pagel J, Hillmen P, Barrientos J, Zelenetz A, Kipps T, Flinn I, Eradat H, Lamanna N, Coiffier B, Pettitt A, Li X, Jahn T, O'Brien S, Hallek M. Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed chronic lymphocytic leukemia. J Geriatr Oncol 2014. [DOI: 10.1016/j.jgo.2014.09.076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
13
|
Yezefski T, Xie H, Walter R, Pagel J, Becker PS, Hendrie P, Sandhu V, Shannon-Dorcy K, Abkowitz J, Appelbaum FR, Estey E. Value of routine 'day 14' marrow exam in newly diagnosed AML. Leukemia 2014; 29:247-9. [PMID: 25204570 DOI: 10.1038/leu.2014.268] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- T Yezefski
- University of Washington School of Medicine, Seattle, WA, USA
| | - H Xie
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - R Walter
- 1] Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA [2] Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA [3] Division of Hematology, Department of Medicine, University of Washington, Seattle, WA, USA
| | - J Pagel
- 1] Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA [2] Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA
| | - P S Becker
- 1] Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA [2] Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA [3] Division of Hematology, Department of Medicine, University of Washington, Seattle, WA, USA
| | - P Hendrie
- Division of Hematology, Department of Medicine, University of Washington, Seattle, WA, USA
| | - V Sandhu
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - K Shannon-Dorcy
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - J Abkowitz
- Division of Hematology, Department of Medicine, University of Washington, Seattle, WA, USA
| | - F R Appelbaum
- 1] Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA [2] Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA
| | - E Estey
- 1] Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA [2] Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA [3] Division of Hematology, Department of Medicine, University of Washington, Seattle, WA, USA
| |
Collapse
|
14
|
Rogenhofer N, Eckert N, Götzfried I, Nguyen T, Pagel J, Kammerer T, Hilferink S, Klug F, Hofmann-Kiefer K, Chouker A, Rehm M, Thaler CJ. Effects of the menstrual cycle on the endothelial glycocalyx (EGX) and leucocyte function. Geburtshilfe Frauenheilkd 2014. [DOI: 10.1055/s-0034-1387999] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
15
|
Kenoyer A, Orozco J, Hamlin D, Wilbur D, Fisher D, Hylarides M, Axtman A, Frayo S, Green D, Gopal A, O'Donnell P, Press O, Pagel J. Haploidentical Bone Marrow Transplantation Using Anti-CD45 Radioimmunotherapy to Decrease Relapse in a Pre-Clinical Murine Model. Biol Blood Marrow Transplant 2012. [DOI: 10.1016/j.bbmt.2011.12.062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
16
|
Pagel J, Lionberger J, Sandhu R, Gooley T, Shannon-Dorcy K, Dean C, Scott B, Sandmaier B, O'Donnell P, Becker P, Petersdorf S, Hendrie P, Sorror M, Holm N, Deeg J, Appelbaum F, Estey E. Frequency of Allogeneic Hematopoietic Cell Transplantation Among High-Risk AML Patients in First Complete Remission at an Academic Center. Biol Blood Marrow Transplant 2012. [DOI: 10.1016/j.bbmt.2011.12.503] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
17
|
Koch F, Pagel J, Ehl S, Griffiths G, Hennies HC, Beutel K, Horstmann M, zur Stadt U. Functional characterisation of Munc18–2 missense mutations in patients with familial hemophagocytic lymphohistiocytosis type 5 (FHL-5). Klin Padiatr 2010. [DOI: 10.1055/s-0030-1254490] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
18
|
|
19
|
Pagel J, Mohorn M, Kloetzer KH, Fleck M, Wendt TG. [The inhalation versus systemic prevention of pneumonitis during thoracic irradiation]. Strahlenther Onkol 1998; 174:25-9. [PMID: 9463561 DOI: 10.1007/bf03038224] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
BACKGROUND Pneumonitis is a typical subacute reaction of healthy bronchial tissue to thoracic irradiation. The purpose of the present trial was to show whether prophylactic application of steroids in the course of and following radiotherapy would reduce the incidence of pneumonitis. PATIENTS AND METHODS Fifty-seven patients receiving thoracic irradiation for bronchial carcinoma were assigned to 2 therapeutic groups; half of the patients were given 10 mg of oral prednisolone per day, while the other half received daily inhalative beclomethasone. All patients were evaluated for radiographic signs of pneumonitis. Thirty-two patients received additional investigations for pulmonary diffusion capacity of carbon monoxide. RESULTS The overall incidence of pneumonitis was 17.6% (10/57 patients). Neither total radiation dose nor mode of fractionation did significantly contribute to the incidence of pneumonitis. Those patients showing a pulmonary diffusion capacity for carbon monoxide of less than 60% prior to radiotherapy had a significantly higher risk of developing pneumonitis (4/7) than patients with a higher diffusion capacity (3/25, p = 0.026). In follow-up period we did not see significant changes in diffusion capacity neither with patients who developed pneumonitis nor with those patients showing no evidence of pulmonary injury. Comparing the chest X-ray there were less radiographic changes consistent with pneumonitis in the inhalative beclomethasone (2/28) than in the oral prednisolone group (8/29, p = 0.045). DISCUSSION In order to reduce the incidence of pneumonitis in patients receiving thoracic irradiation we support a continuous application of steroids in the course of and following radiotherapy. The inhalative use of beclomethasone has proved to be superior to oral prednisolone due to better local efficacy and decreased unwanted side effects.
Collapse
Affiliation(s)
- J Pagel
- Abteilung Strahlentherapie, Klinik und Poliklinik für Radiologie, Friedrich-Schiller-Universität Jena
| | | | | | | | | |
Collapse
|
20
|
Abstract
LEF-1 (lymphoid enhancer-binding factor 1) is a cell type-specific member of the family of high mobility group (HMG) domain proteins that recognizes a specific nucleotide sequence in the T cell receptor (TCR) alpha enhancer. In this study, we extend the analysis of the DNA-binding properties of LEF-1 and examine their contributions to the regulation of gene expression. We find that LEF-1, like nonspecific HMG-domain proteins, can interact with irregular DNA structures such as four-way junctions, albeit with lower efficiency than with specific duplex DNA. We also show by a phasing analysis that the LEF-induced DNA bend is directed toward the major groove. In addition, we find that the interaction of LEF-1 with a specific binding site in circular DNA changes the linking number of DNA and unwinds the double helix. Finally, we identified two nucleotides in the LEF-1-binding site that are important for protein-induced DNA bending. Mutations of these nucleotides decrease both the extent of DNA bending and the transactivation of the TCR alpha enhancer by LEF-1, suggesting a contribution of protein-induced DNA bending to the function of TCR alpha enhancer.
Collapse
Affiliation(s)
- K Giese
- Howard Hughes Medical Institute, Department of Microbiology, University of California, San Francisco 94143-0414, USA
| | | | | |
Collapse
|
21
|
Raudat CW, Pagel J, Woodhall D, Wojtanowski M, Van Bergen R. Early intervention and aggressive management of infected median sternotomy incision: a review of 2242 open-heart procedures. Am Surg 1997; 63:238-41; discussion 241-2. [PMID: 9036891] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Infected median sternotomy following open-heart surgery is a devastating complication with an incidence of 0.4 to 5 per cent and mortality as high as 80 per cent. Management varies from irrigation, debridement, closure with muscle, and skin flaps. We present our experience of early intervention and aggressive single-stage operative management. A retrospective chart review of all open-heart surgery patients was conducted from September 1984 through September 1994. Of the 2242 patients, 52 had infected median sternotomy incisions (2.3% incidence). The mean length of stay for reconstructive procedures was 18 days. The median interval to detection was 15 days, whereas the median interval to intervention was 4 days. There were five (6.8%) failed procedures and nine (12.3%) staged procedures. There were six deaths (11.5% incidence), one prior to receiving operative intervention. There was one false aneurysm. Single-stage reconstruction is safe, with results better than multistage procedures. It may be safely performed with a high success rate (93%). Early recognition and intervention significantly decreases length of stay.
Collapse
Affiliation(s)
- C W Raudat
- Department of Surgery, Fairview Hospital, Cleveland, Ohio 44111, USA
| | | | | | | | | |
Collapse
|
22
|
Giese K, Pagel J, Grosschedl R. Distinct DNA-binding properties of the high mobility group domain of murine and human SRY sex-determining factors. Proc Natl Acad Sci U S A 1994; 91:3368-72. [PMID: 8159753 PMCID: PMC43578 DOI: 10.1073/pnas.91.8.3368] [Citation(s) in RCA: 83] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
The mammalian sex-determining gene SRY (sex-determining region on Y chromosome) encodes a member of the high mobility group (HMG) family of regulatory proteins. The HMG domain of the SRY protein represents a DNA binding motif that displays rather unusually weak evolutionary conservation of amino acids between human and mouse sequences. Together with the previous finding that the human (h) SRY gene is unable to induce a male phenotype in genetically female transgenic mice, these observations raise questions concerning the DNA binding properties of SRY proteins. Here, we present data that indicate that the DNA binding and bending properties of the HMG domains of murine (m) SRY and hSRY differ from each other. In comparison, mSRY shows more-extensive major-groove contacts with DNA and a higher specificity of sequence recognition than hSRY. Moreover, the extent of protein-induced DNA bending differs from the HMG domains of hSRY and mSRY. These differences in DNA binding by hSRY and mSRY may, in part, account for the functional differences observed with these gene products.
Collapse
Affiliation(s)
- K Giese
- Howard Hughes Medical Institute, University of California, San Francisco 94143-0414
| | | | | |
Collapse
|
23
|
Abstract
The high-mobility group (HMG) domain is a DNA-binding motif that is shared abundant non-histone components of chromatin and by specific regulators of transcription and cell differentiation. The HMG family of proteins comprises members with multiple HMG domains that bind DNA with low sequence specificity, and members with single HMG domains that recognize specific nucleotide sequences. Common properties of HMG domain proteins include interaction with the minor groove of the DNA helix, binding to irregular DNA structures, and the capacity to modulate DNA structure by bending. DNA bending induced by the HMG domain can facilitate the formation of higher-order nucleoprotein complexes, suggesting that HMG domain proteins may have an architectural role in assembling such complexes.
Collapse
Affiliation(s)
- R Grosschedl
- Department of Microbiology, University of California, San Francisco 94143-0414
| | | | | |
Collapse
|
24
|
Abstract
Twenty patients with advanced carcinoma of the uterine cervix were treated for at least 3 months with 5 mg bromocriptine daily. No remissions were found (95% confidence limits, 0-17%), neither among normo- nor among hyperprolactinemic patients. Twelve had stable disease for 2-9 months with a median of 3 months. The results of this study does not support the hypothesis that bromocriptine possesses any antitumor effect in cancer of the uterine cervix.
Collapse
|
25
|
Pagel J, Bock JE. Endometrial cancer. A review. Dan Med Bull 1984; 31:333-45. [PMID: 6383739] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
|
26
|
Pagel J, Wood T. Transport patterns and complications in an isolated Alaska practice. J Fam Pract 1983; 16:957-962. [PMID: 6842152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/21/2023]
Abstract
This study reviews the patterns of transport and complications that occurred in 169 cases of transporting patients over a four-year period for a small, isolated Alaskan community in which the physicians as a matter of policy attempted to avoid heroic emergency surgery. Case descriptions are included describing transport-related complications and mortality and morbidity of patients transferred. A low incidence of mortality and relatively little long-term morbidity was experienced, supporting the feasibility of transferring severely ill patients rather than attempting heroic surgery under marginal circumstances. Although the lack of comparable studies limits the usefulness of these findings in assessing the overall quality of care, appropriate utilization of transport as an extension of the physician's capabilities resulted in a low incidence of complications during the study period.
Collapse
|
27
|
Pagel J, Hjortsø E. [Hyperkalemia during bilateral embolectomy in the common iliac arteries]. Ugeskr Laeger 1983; 145:498-9. [PMID: 6845518] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|
28
|
|
29
|
Petersen JK, Pagel J. [Colonic lipoma]. Ugeskr Laeger 1979; 141:2893-4. [PMID: 505601] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|
30
|
Quayle ES, Pagel J, Monti JA, Christian ST. A serotonin sensitive guanylate cyclase associated with specific neurotransmitter binding sites on isolated synaptic membranes from mature rat brain. Life Sci 1978; 23:159-65. [PMID: 28459 DOI: 10.1016/0024-3205(78)90265-5] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
31
|
Christian ST, Harrison R, Quayle E, Pagel J, Monti J. The in vitro identification of dimethyltryptamine (DMT) in mammalian brain and its characterization as a possible endogenous neuroregulatory agent. Biochem Med 1977; 18:164-83. [PMID: 20877 DOI: 10.1016/0006-2944(77)90088-6] [Citation(s) in RCA: 41] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
32
|
Quayle ES, Pagel J, Monti JA, Christian ST. Specific serotonin binding and adenylate cyclase stimulation: a correlative study using isolated synaptosomal membranes from mature rat brain. Ala J Med Sci 1977; 14:259-63. [PMID: 196516] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
33
|
|
34
|
Christian ST, Harrison R, Pagel J. Evidence for dimethyltryptamine (DMT) as a naturally-occurring transmitter in mammalian brain. Ala J Med Sci 1976; 13:162-5. [PMID: 4987] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
35
|
|
36
|
Nielsen OV, Malmström J, Pagel J, Efsen F. Treatment of extrahepatic obstruction of the portal vein system. Scand J Gastroenterol 1973; 8:599-604. [PMID: 4543748] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/09/2022]
|
37
|
Pagel J. Zum 50jährigen Jubiläum der Berliner Medizinischen Gesellschaft. Dtsch Med Wochenschr 1910. [DOI: 10.1055/s-0028-1143155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
38
|
Pagel J. Curpfuscherthum im Lichte der Geschichte der Medicin. Dtsch Med Wochenschr 1889. [DOI: 10.1055/s-0029-1198430] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
39
|
Pagel J. Curpfuscherthum im Lichte der Geschichte der Medicin (Schluss aus No. 19.). Dtsch Med Wochenschr 1889. [DOI: 10.1055/s-0029-1198446] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|